A Protocol To Monitor From Birth To Age 15 Months The Neurological Development Of Infants With Exposure In-utero In Tanezumab Clinical Studies At All Investigational Sites
Phase of Trial: Phase III
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Tanezumab (Primary)
- Indications Back pain; Cancer pain
- Focus Adverse reactions
- Sponsors Pfizer
- 19 Dec 2017 Planned End Date changed from 1 Jul 2020 to 10 Jul 2020.
- 19 Dec 2017 Planned primary completion date changed from 1 Jan 2020 to 12 Jan 2020.
- 13 Dec 2017 Status changed from not yet recruiting to recruiting.